Belantamab mafodotin: an important treatment option for vulnerable patients with triple class exposed relapsed and/or refractory multiple myeloma

Maria Victoria Mateos  1 , Katja Weisel  2 , Evangelos Terpos  3 , Sossana Delimpasi  4 , Efstathios Kastritis  3 , Elena Zamagni  5 , Michel Delforge  6 , Enrique Ocio  7 , Eirini Katodritou  8 , Francesca Gay  9 , Alessandra Larocca  9 , Xavier Leleu  10 , Paula Rodriguez Otero  11 , Fredik Schjesvold  12 , Michele Cavo  13 , Meletios A Dimopoulos  3